| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/CBT.13.1.18438 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.4161/cbt.13.1.18438 |
| https://doi.org/10.4161/cbt.13.1.18438 | ||
| https://europepmc.org/articles/PMC3335980 | ||
| https://europepmc.org/articles/PMC3335980?pdf=render | ||
| https://www.tandfonline.com/doi/pdf/10.4161/cbt.13.1.18438?needAccess=true | ||
| P932 | PMC publication ID | 3335980 |
| P698 | PubMed publication ID | 22198566 |
| P5875 | ResearchGate publication ID | 51924279 |
| P50 | author | Shannon N. Westin | Q59165937 |
| P2093 | author name string | Russell R. Broaddus | |
| P2860 | cites work | Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? | Q22241958 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
| Journal of Clinical Oncology | Q400292 | ||
| Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells | Q39524625 | ||
| Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family | Q39569822 | ||
| Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines | Q39597656 | ||
| Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells | Q39618491 | ||
| PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors | Q39644716 | ||
| Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer | Q39813785 | ||
| Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition | Q40169788 | ||
| Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells | Q40216291 | ||
| Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines | Q40252973 | ||
| Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. | Q40327522 | ||
| High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma | Q40345165 | ||
| Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study | Q40533016 | ||
| Somatic mutations are present in all members of the AKT family in endometrial carcinoma | Q42593226 | ||
| Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. | Q42953723 | ||
| Chemoprevention of Breast Cancer: A Model for Change | Q43843438 | ||
| Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma | Q44004637 | ||
| Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas | Q45258362 | ||
| Abnormalities of the APC/beta-catenin pathway in endometrial cancer | Q45345268 | ||
| mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets | Q45941008 | ||
| Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. | Q46035627 | ||
| Predictors of competing mortality in advanced head and neck cancer | Q46215317 | ||
| Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer | Q46859430 | ||
| Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer | Q46878046 | ||
| Clinical significance of microsatellite instability in endometrial carcinoma | Q53331560 | ||
| Cixutumumab | Q24609058 | ||
| Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials | Q24625201 | ||
| Targeting the mTOR signaling network for cancer therapy | Q24658334 | ||
| Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis | Q24684263 | ||
| Targeting of the BRAF gene in papillary thyroid carcinoma (review) | Q27277515 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study | Q27851528 | ||
| Wnt signaling and cancer | Q27860871 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers | Q28145813 | ||
| The Hedgehog and Wnt signalling pathways in cancer | Q28189485 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| PTEN1 is frequently mutated in primary endometrial carcinomas | Q28250937 | ||
| Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma | Q28251010 | ||
| Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma | Q28267816 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Exploiting the PI3K/AKT pathway for cancer drug discovery | Q29615120 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. | Q30439393 | ||
| A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. | Q30442540 | ||
| Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer | Q30497303 | ||
| Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy | Q33316645 | ||
| Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. | Q33386403 | ||
| AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma | Q33512169 | ||
| The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer | Q33557369 | ||
| Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype | Q53386191 | ||
| PTEN/MMAC1 mutations in endometrial cancers | Q53439663 | ||
| RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma | Q53599377 | ||
| PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. | Q54584081 | ||
| Insulin-like growth factors and cancer | Q56336667 | ||
| Overexpression of HER-2/neu in uterine serous papillary cancer | Q57218889 | ||
| Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia | Q57240019 | ||
| Low frequency ofBRAFandCDKN2Amutations in endometrial cancer | Q57664882 | ||
| Endometrial cancer | Q63199203 | ||
| Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium | Q67879210 | ||
| Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma | Q73117118 | ||
| Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma | Q73403855 | ||
| The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways | Q73459314 | ||
| PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases | Q73622060 | ||
| Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas | Q73629159 | ||
| Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis | Q74116705 | ||
| K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome | Q77763896 | ||
| E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium | Q78617949 | ||
| PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia | Q79297568 | ||
| Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium | Q79330539 | ||
| Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study | Q80390603 | ||
| Her-2/neu overexpression and amplification in uterine papillary serous carcinoma | Q80396741 | ||
| Cancer: the road to Amiens | Q82877400 | ||
| Metformin Reverses Progestin Resistance in Endometrial Cancer Cells by Downregulating GloI Expression | Q83306439 | ||
| Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors | Q83390295 | ||
| Overcoming resistance: Targeting the PI3K/mTOR pathway in endocrine refractory breast cancer | Q84115184 | ||
| Phase 0 Clinical Trials in Oncology: An Exploratory Methodology for Constructing a Study With Patients Undergoing Surgery for Metastatic Disease | Q85024128 | ||
| Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab | Q36982859 | ||
| Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis | Q36997611 | ||
| Clinical and biological significance of vascular endothelial growth factor in endometrial cancer | Q37038244 | ||
| The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas | Q37269747 | ||
| Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases | Q37274044 | ||
| Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma | Q37349875 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| FGFR2 as a molecular target in endometrial cancer | Q37401322 | ||
| A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma | Q37432527 | ||
| Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy | Q37463664 | ||
| The role of fibroblast growth factors in tumor growth | Q37512303 | ||
| Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. | Q37563971 | ||
| Dasatinib in solid tumors | Q37683766 | ||
| Sunitinib for the management of advanced renal cell carcinoma | Q37705402 | ||
| Targeting endocrine resistance: is there a role for mTOR inhibition? | Q37813287 | ||
| Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions | Q37813289 | ||
| Novel mitogen-activated protein kinase kinase inhibitors | Q37828536 | ||
| Methodological and practical challenges for personalized cancer therapies | Q37848661 | ||
| Integrating biomarkers in clinical trials | Q37853183 | ||
| Anti‐EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab | Q37856053 | ||
| The landscape of EGFR pathways and personalized management of non-small-cell lung cancer | Q37861196 | ||
| Metformin as an antitumor agent in cancer prevention and treatment | Q37883608 | ||
| Present and future of PI3K pathway inhibition in cancer: perspectives and limitations | Q37886008 | ||
| Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. | Q38425937 | ||
| Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer | Q33820455 | ||
| Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes | Q33855646 | ||
| Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression | Q33858186 | ||
| Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma | Q33918399 | ||
| PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. | Q33958963 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| The EGF receptor family as targets for cancer therapy | Q34293543 | ||
| Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study | Q34497010 | ||
| BRAF somatic mutations in malignant melanoma and melanocytic naevi | Q34506145 | ||
| Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab | Q34679166 | ||
| Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum | Q34682062 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer | Q34778936 | ||
| Prospective evaluation of insulin resistance among endometrial cancer patients | Q34859018 | ||
| Targeting the epidermal growth factor receptor for cancer therapy | Q34863779 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study | Q35023418 | ||
| Pharmacogenetics and pharmacogenomics of anticancer agents. | Q35030489 | ||
| PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer | Q35050913 | ||
| Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations | Q35051154 | ||
| EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer | Q35114341 | ||
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 | ||
| Akt inhibitors in clinical development for the treatment of cancer | Q35628576 | ||
| Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification | Q35640925 | ||
| Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene | Q35681816 | ||
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | Q36042091 | ||
| The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer | Q36317650 | ||
| Epidermal growth factor receptor (EGFR) signaling in cancer | Q36353031 | ||
| Predicting benefit from anti-angiogenic agents in malignancy | Q36534760 | ||
| Molecular and pathologic aspects of endometrial carcinogenesis | Q36617660 | ||
| Drug-sensitive FGFR2 mutations in endometrial carcinoma | Q36735178 | ||
| Hormone therapy in advanced and recurrent endometrial cancer: a systematic review | Q36794868 | ||
| The role of the EGFR signaling in tumor microenvironment. | Q36951215 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endometrial cancer | Q944777 |
| P304 | page(s) | 1-13 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Personalized therapy in endometrial cancer: challenges and opportunities | |
| Personalized therapy in endometrial cancer: Challenges and opportunities | |||
| P478 | volume | 13 |
| Q92618449 | Amniotic epithelial cells reverse abnormal vascular structure and function in endometrial carcinoma |
| Q54940052 | Computational development of a molecular-based approach to improve risk stratification of endometrial cancer patients. |
| Q30358081 | Destructive effect of HIFU on rabbit embedded endometrial carcinoma tissues and their vascularities |
| Q33675285 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. |
| Q28074769 | Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas |
| Q54940815 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. |
| Q34571141 | Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma |
| Q57828031 | Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma |
| Q52624560 | Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women |
| Q45783398 | Identification of thymosins β4 and β 10 in paediatric craniopharyngioma cystic fluid |
| Q37081947 | Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers |
| Q36905799 | Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery. |
| Q43551349 | Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma |
| Q64935425 | Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study. |
| Q37209603 | Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. |
| Q37006856 | Personalized care in uterine cancer |
| Q54326161 | Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer |
| Q55368257 | Predicting high-risk endometrioid carcinomas using proteins. |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q37406760 | Progesterone receptor isoforms A and B: new insights into the mechanism of progesterone resistance for the treatment of endometrial carcinoma |
| Q47953629 | Progesterone-mediated angiogenic activity of endothelial progenitor cell and angiogenesis in traumatic brain injury rats were antagonized by progesterone receptor antagonist. |
| Q52645865 | Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells. |
| Q36843378 | Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults |
| Q38716477 | Surgical treatment of high stage endometrial cancer: current perspectives |
| Q34401785 | Targeting hypoxia in the leukemia microenvironment |
| Q33708546 | The expression pattern of 19 genes predicts the histology of endometrial carcinoma |
| Q36151896 | The genomics and genetics of endometrial cancer |
| Q44522454 | Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice |
Search more.